Heme oxygenase-1-derived carbon monoxide enhances the host defense response to microbial sepsis in mice.
Sepsis is characterized by a systemic response to severe infection. Although the inflammatory phase of sepsis helps eradicate the infection, it can have detrimental consequences if left unchecked. Therapy directed against inflammatory mediators of sepsis has shown little success and has the potential to impair innate antimicrobial defenses. Heme oxygenase-1 (HO-1) and the product of its enzymatic reaction, CO, have beneficial antiinflammatory properties, but little is known about their effects on microbial sepsis. Here, we have demonstrated that during microbial sepsis, HO-1-derived CO plays an important role in the antimicrobial process without inhibiting the inflammatory response. HO-1-deficient mice suffered exaggerated lethality from polymicrobial sepsis. Targeting HO-1 to SMCs and myofibroblasts of blood vessels and bowel ameliorated sepsis-induced death associated with Enterococcus faecalis, but not Escherichia coli, infection. The increase in HO-1 expression did not suppress circulating inflammatory cells or their accumulation at the site of injury but did enhance bacterial clearance by increasing phagocytosis and the endogenous antimicrobial response. Furthermore, injection of a CO-releasing molecule into WT mice increased phagocytosis and rescued HO-1-deficient mice from sepsis-induced lethality. These data advocate HO-1-derived CO as an important mediator of the host defense response to sepsis and suggest CO administration as a possible treatment for the disease.
Chung
Su Wol
SW
Division of Pulmonary and Critical Care Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA.
Liu
Xiaoli
X
Macias
Alvaro A
AA
Baron
Rebecca M
RM
Perrella
Mark A
MA
D000818:Animals; D000963:Antimetabolites / Q000276:immunology / Q000494:pharmacology*; D002248:Carbon Monoxide / Q000378:metabolism / Q000494:pharmacology*; D013293:Enterococcus faecalis; D004926:Escherichia coli; D004927:Escherichia coli Infections / Q000188:drug therapy / Q000201:enzymology / Q000235:genetics / Q000473:pathology; D005347:Fibroblasts / Q000201:enzymology / Q000473:pathology; D018390:Gene Targeting; D016908:Gram-Positive Bacterial Infections / Q000188:drug therapy / Q000201:enzymology / Q000235:genetics; D051547:Heme Oxygenase-1 / Q000235:genetics / Q000276:immunology*; D006801:Humans; D007113:Immunity, Innate / Q000187:drug effects* / Q000235:genetics; D007249:Inflammation / Q000188:drug therapy / Q000201:enzymology / Q000235:genetics / Q000382:microbiology / Q000473:pathology; D018836:Inflammation Mediators / Q000037:antagonists & inhibitors / Q000378:metabolism; D051379:Mice; D018345:Mice, Knockout; D032389:Myocytes, Smooth Muscle / Q000201:enzymology / Q000473:pathology; D010587:Phagocytosis / Q000187:drug effects* / Q000235:genetics; D018805:Sepsis / Q000188:drug therapy / Q000201:enzymology* / Q000235:genetics / Q000382:microbiology / Q000473:pathology
D000963:Antimetabolites; D018836:Inflammation Mediators; D002248:Carbon Monoxide; D051547:Heme Oxygenase-1